Exchange: NASDAQ·Updated 05:06 PM EST

CELZ News

News
all
press releases
Creative Medical Extends Breakout as Patent Momentum Fuels Continued Buying Interest
Creative Medical (NASDAQ:CELZ) is continuing to attract investor attention after building on yesterday's patent-driven rally, with shares reaching an intraday high of $1.94 as momentum carried into a second trading session. The latest move follows news that the U.S. Patent and Trademark Office issued a Notice of Allowance for a new patent covering the company's exosome-based immunotherapy platform targeting Type 1 diabetes, further strengthening its growing intellectual property portfolio.
24-7 Market News
Creative Medical Extends Breakout as Patent Momentum Fuels Continued Buying Interest
Creative Medical (NASDAQ:CELZ) is continuing to attract investor attention after building on yesterday's patent-driven rally, with shares reaching an intraday high of $1.94 as momentum carried into a second trading session. The latest move follows news that the U.S. Patent and Trademark Office issued a Notice of Allowance for a new patent covering the company's exosome-based immunotherapy platform targeting Type 1 diabetes, further strengthening its growing intellectual property portfolio.
24-7 Market News
More News
Creative Medical (NASDAQ:CELZ) could remain one to watch after attracting investor attention following yesterday’s reaction to news that the U.S. Patent and Trademark Office issued a Notice of Allowance for a new patent covering its exosome-based immunotherapy platform targeting Type 1 diabetes. The announcement added another layer of intellectual property protection to the company's expanding regenerative medicine portfolio and highlighted its strategy of building multiple therapeutic approaches aimed at one of the largest unmet needs in autoimmune disease.
24-7 Market News
Creative Medical Technology Holdings Inc. (NASDAQ: CELZ) shares are surging Thursday afternoon following an intellectual property milestone.read more...
Benzinga
Gainers Creative Medical Tech (NASDAQ:CELZ) stock increased by 107.8% to $1.39 during Thursday's regular session. The company's market cap stands at $4.3 million. Ensysce Biosciences (NASDAQ:ENSC) stock roseread more...
Benzinga
Gainers Creative Medical Tech (NASDAQ:CELZ) stock moved upwards by 31.4% to $0.88 during Wednesday's after-market session. The company's market cap stands at $4.2 million. Caris Life Sciences (NASDAQ:CAI)read more...
Benzinga
Gainers Creative Medical Tech (NASDAQ:CELZ) stock moved upwards by 242.5% to $2.77 during Tuesday's regular session. The market value of their outstanding shares is at $2.9 million. Cuprina Holdings (Cayman)read more...
Benzinga
Creative Medical Technology, Baiya International Group, and GD Culture Group shares slumped to their 52-week lows amid divestiture and fundraising updates.
Stocktwits
Creative Medical Technology Holdings, Inc. (CELZ) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Zacks
The company estimates that the potential market for innovative treatments for spinal disorders could exceed $20 billion by 2030.
Stocktwits
CELZ, GRFS and WHR have been added to the Zacks Rank #5 (Strong Sell) List on July 31, 2025.
Zacks

Advertisement|Remove ads.